AstraZeneca shares rose after the company said a drug candidate met the primary goal in two late-stage trials for a deadly lung disease, clearing the path to seek approval from regulators. The U.K.

FILE PHOTO: An AstraZeneca sign is seen at the third China International Import Expo (CIIE) in Shanghai, China November 6, 2020. REUTERS/Aly Song/File Photo March 27 (Reuters) - AstraZeneca said on ...

Regeneron Pharmaceuticals stock slumped on Friday after two late-stage trials for an experimental drug co-developed with Sanofi only partially met goals. Regeneron sank 17% to $501.58 while ...

Sept 17 (Reuters) - AstraZeneca (AZN.L), opens new tab said on Wednesday its asthma drug Fasenra failed to control the rate of flare-ups in patients with chronic obstructive pulmonary disease (COPD) ...

This corrects the date that the BMO Capital note was published. Shares of Regeneron Pharmaceuticals Inc. were having their worst day in more than a decade on Friday after a shocking failure in a ...

Altesa BioSciences, a clinical-stage pharmaceutical company dedicated to preventing and treating the leading cause of COPD and asthma exacerbations, today announced it will be presenting its abstract ...

Regeneron Pharmaceuticals, Inc. REGN and partner Sanofi SNY announced mixed results from two late-stage studies, AERIFY-1 and AERIFY-2, on itepekimab for the treatment of chronic obstructive pulmonary ...

AstraZeneca shares rose after the company said a drug candidate met the primary goal in two late-stage trials for a deadly lung disease, clearing the path to seek approval from regulators. The U.K.